Oral ensartinib is effective in patients with co-existing ALK fusion and point mutations
Zhijian Yao,
Xin Li,
Xiyu An,
Dongyu Cui
Affiliations
Zhijian Yao
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Xin Li
Department of Otolaryngology, Gansu Provincial People's Hospital, Lanzhou, China
Xiyu An
Department of Imaging, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Dongyu Cui
Corresponding author. 12 Jiankang Road, Chang 'an District, Shijiazhuang city, Hebei Province, 050000, China.; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China